{"name":"Protara Therapeutics","slug":"protara-therapeutics","ticker":"","exchange":"","domain":"protara.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQSWd6dnUxYi1QTy1scDdFZEUyS1VpYWNya3Q2SW9xWl9rR21NZ2VZdzAtQTZfczJXdThzMkJ5MWRvc196QXFvanhDbXZOdUVmNEJxZ2ZJVHJQVlJJUHoybzFhNVV2WDFHLWkyeEdxbGtGWF9EMFhUMFJ5RzJIS2xjY2cxSzFEdw?oc=5","date":"2026-03-04","type":"pipeline","source":"Seeking Alpha","summary":"Protara gains as JP Morgan starts at overweight - Seeking Alpha","headline":"Protara gains as JP Morgan starts at overweight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOQllPbHdkb2xNNFdleWdmVEVZa1pwRjAtbmxfcFVnMTBsczA4MFphbF8wUzFLNTI2N1RPdE4zWThobkFjQzJaUEE0WDREVXA2eFdXcnJNUkdiUk5PdmpQRGFsbzZrLVVLazhzYTFQM3NDS0VDb0VWTFNvVnd4SmNqMmxGRmRxbGE2MjFwYkNYVDdWT0t6aERyUThUUnltYVR3Vjhzb3VPcjUycGxVekZHWk9Nbkd3UQ?oc=5","date":"2026-03-01","type":"pipeline","source":"The Pharma Letter","summary":"The week in pharma: action, reaction and insight – week to February 27, 2026 - The Pharma Letter","headline":"The week in pharma: action, reaction and insight – week to February 27, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNN01vclNBVkhlUHgyak1YWmFhUHRMbnVRT1AydklZdnZZVkxMRE9JX0dEeHhOQWFlUDYxOENBMnJkdzBqdE1XeEhMUjM4M3pseE5KNUhvTjc1Zzk5RFhXVkg2VHNPOF9mU2ZvblJrb1lnd2Q1SERBZWxvS1NMZlpvbEZxNGpRd1d6UzQ1bG00NVZkQy11T2lNd1VFd05FbFlwQnV6cUZpT3hiQVNBekE?oc=5","date":"2026-02-24","type":"pipeline","source":"Fierce Biotech","summary":"Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months - Fierce Biotech","headline":"Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5iLXllSFhNMjFiZ19hS1ZLTVJmckZYT29PX2hLYXFBaU5uZjczYTNzNlZQQzJMS1BScWdNUnR1bV9MQ3FwMHhmQlhpdkhMdXg1dG9N?oc=5","date":"2026-02-24","type":"pipeline","source":"FirstWord Pharma","summary":"Protara's bladder cancer therapy earns kudos amid choppy market reaction - FirstWord Pharma","headline":"Protara's bladder cancer therapy earns kudos amid choppy market reaction","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-15","type":"pipeline","source":"simplywall.st","summary":"Protara Therapeutics, Inc. (NASDAQ:TARA) down to US$264m market cap, but institutional owners may not be as affected after a year of 5.8% returns - simplywall.st","headline":"Protara Therapeutics, Inc. (NASDAQ:TARA) down to US$264m market cap, but institutional owners may not be as affected aft","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQeHBzdVJEZVRNeUcxSkpnSXVzUXdvZnh4YWdLQWt1ak90dlVXQm5OaldLc1JGanpSTGE0SGhvQXcyenpLa3QyRmdzc3hLN0p3eXJ3WWtDTWNPcnkxUlNfU1VoeDhMOWxwVkRwZVBrZXZPTUVrYUdaVFNlYnZvNjlEY01KYU5rTUhkd2dyejVXb2gwVnB3RFZMdkNyZEh6dw?oc=5","date":"2026-01-05","type":"pipeline","source":"The Pharma Letter","summary":"Protara Therapeutics updates on TARA-002 development - The Pharma Letter","headline":"Protara Therapeutics updates on TARA-002 development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMjFvb25YNl8yUlA3U1JUZDhia3FXV2MyclEzcW40QkN4SWppa2lfdHdraGNLaVVmMHcxOUZNaC03ZVlGMzdsX1g3eXI3aTVzaE0xUDE3aG84TUhKOG9Qa0RYM21oRmJrdnlrcUh6bjNheG9rWDREZUxEMFRuTmRlMHU2Q0k0ZHR5T0FNR2o4TTdUSWxEMHh3NEItNkxyYWthQWFWeXhmNC12dHM?oc=5","date":"2025-12-05","type":"trial","source":"endpoints.news","summary":"Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara - endpoints.news","headline":"Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQamJSYy03X0I1YUs2bWl2ZGR1dU5PMFpBaEhUOGpmam0zNWZ6MWowNmRUek1rNjVDVmQwb3VPYUwxWU5rcVpPVmVyUmN6dWE3Q1l2eUc1VlpEVE1WdDRhMW5fVkFZbXFGMTBVcVNyVm01T3g5cDJNeWNOQUN3OTdqMkxMSHdTX1VWTFp4bi16dnh1ZURxS1FKSmZQeklDZHdlbDN3NHE3c0ZmRG1JSUc1NGpDaw?oc=5","date":"2025-11-19","type":"trial","source":"PharmaTimes","summary":"TARA-002 shows strong early results in trial for paediatric lymphatic malformations - PharmaTimes","headline":"TARA-002 shows strong early results in trial for paediatric lymphatic malformations","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-24","type":"pipeline","source":"simplywall.st","summary":"Could Greater Index Exposure for Protara Therapeutics (TARA) Shift Its Path to Broader Investor Interest? - simplywall.st","headline":"Could Greater Index Exposure for Protara Therapeutics (TARA) Shift Its Path to Broader Investor Interest?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQZTNsMlRHT2RRUkQ3aE9STnpZTUJMSWNQTjJEWUc0Xy0yMHRjX2dFOWdILVdSdlF5WE1iRExGYjMtM2ZzN3RhWEVRNUdsQnVzT2thTHZrZElscWVsdElnTE5jVlhiVk5uMTdCQXAtV280MDAzRHRLemtvbE84enNhVXhDa2Nfb2ZfUnc?oc=5","date":"2025-09-24","type":"pipeline","source":"Yahoo Finance","summary":"A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index - Yahoo Finance","headline":"A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOOHlDMVduVEt1X3lrQW0tSS10a0hQdEJMWUh6dG16bzc4ZXRTdS1aMzB4QjVaNVRvTWh6U244UDNoQWtmTllJNkdqV1VNWHRQTXlSWlRucEdBQ2ZlRGx1V3lCek9NeGxzWHF2dGNPeTMzdk81QjN0dVlUMEVyU0IwZ19sbkp4WlYzNjFYNXI0eFJMTl9FUm5PWEdRTU9ocjVxUFFQZWZVUl9sVUZlY3V2dGQzbw?oc=5","date":"2025-09-15","type":"pipeline","source":"Fierce Biotech","summary":"Identifying Undervalued and Overlooked Assets to Address Unmet Patient Needs - Fierce Biotech","headline":"Identifying Undervalued and Overlooked Assets to Address Unmet Patient Needs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPLVc3ZUY5ZVBKbmhJWlZnZ0YwaDlOb2tiWDk2YVNEdTFSX2h6RDJzT01BMFI4cHRHSEJQenVjVGRSR1IyaDU0V1dDaUdzWlZKYmN0UmR6d1NNcEJtVVN6cmFhY2FCRmI2SU9yRmItTF9TOG1WcXZPMWZnWml0aVZITUdLZngxN1Q4enpUZXI2eFdSQXoyN2dZ?oc=5","date":"2025-06-06","type":"pipeline","source":"Fierce Biotech","summary":"Protara gears up for next commercial steps—Chutes & Ladders - Fierce Biotech","headline":"Protara gears up for next commercial steps—Chutes & Ladders","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}